Purpose: To assess the efficacy and safety of intravitreal bevacizumab in central and branch retinal vein occlusion.
Methods: Prospective study, 18 patients, 19 eyes in branch retinal vein occlusion, and 37 patients and 37 eyes in central retinal vein occlusion; preoperative and postoperative assessment: visual acuity, fundus biomicroscopy, optical coherence tomography (OCT).
Results: Visual acuity improves in 84% in central retinal vein occlusion (OVCR) and 73.33% in branch retinal vein occlusion (BRVO) at 1 month after the third injection.
Conclusions: Bevacizumab may play a role in the treatment of central and branch retinal vein occlusion.
Bevacizumab for Macular Edema in Branch and Central Retinal Vein Occlusion
Keywords: macular oedema, best corrected visual acuit, retinal vein occlusion., intravitreal bevacizumab
Full text: PDF